Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aziyo Biologics (ELUT)
NASDAQ:ELUT
Holding ELUT?
Track your performance easily
ELUT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.96 - $5.24
Previous Close$4.84
Volume169.47K
Average Volume (3M)37.02K
Market Cap
$122.00M
Enterprise Value$118.90M
Total Cash (Recent Filing)$25.74M
Total Debt (Recent Filing)$22.64M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Feb 26, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding34,562,098
10 Day Avg. Volume57,825
30 Day Avg. Volume37,016
Standard Deviation0.24
R-Squared0.03
Alpha-0.00121
Financial Highlights & Ratios
Price to Book (P/B)-4.17
Price to Sales (P/S)8.60
Price to Cash Flow (P/CF)-9.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.39
Enterprise Value/Gross Profit10.76
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$10.00Price Target Upside106.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Aziyo Biologics News
PremiumCompany Announcements
Elutia Inc. Reports Strong Q3 Results, Prepares for Major Product Launch
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELUT FAQ
What was Aziyo Biologics’s price range in the past 12 months?
Aziyo Biologics lowest stock price was $1.96 and its highest was $5.24 in the past 12 months.
What is Aziyo Biologics’s market cap?
Currently, no data Available
When is Aziyo Biologics’s upcoming earnings report date?
Aziyo Biologics’s upcoming earnings report date is Feb 26, 2025 which is in 66 days.
How were Aziyo Biologics’s earnings last quarter?
Aziyo Biologics released its earnings results on Nov 14, 2024. The company reported -$0.688 earnings per share for the quarter, missing the consensus estimate of -$0.44 by -$0.248.
Is Aziyo Biologics overvalued?
According to Wall Street analysts Aziyo Biologics’s price is currently Undervalued.
Does Aziyo Biologics pay dividends?
Aziyo Biologics does not currently pay dividends.
What is Aziyo Biologics’s EPS estimate?
Aziyo Biologics’s EPS estimate is -$0.25.
How many shares outstanding does Aziyo Biologics have?
Aziyo Biologics has 30,248,692 shares outstanding.
What happened to Aziyo Biologics’s price movement after its last earnings report?
Aziyo Biologics reported an EPS of -$0.688 in its last earnings report, missing expectations of -$0.44. Following the earnings report the stock price went down -7.05%.
Which hedge fund is a major shareholder of Aziyo Biologics?
Among the largest hedge funds holding Aziyo Biologics’s share is Platinum Investment Management. It holds Aziyo Biologics’s shares valued at N/A.
---
Aziyo Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (106.61% Upside)
$10.00 (106.61% Upside)
Blogger Sentiment
Bullish
ELUT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 188.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.31%
Trailing 12-Months
Company Description
Aziyo Biologics
Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
---
ELUT Company Deck
---
ELUT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view, with significant achievements in the introduction and adoption of the EluPro product line and growth in the SimpliDerm segment. However, there were also challenges, including a slight decrease in sales and increased operating expenses. The overall sentiment is cautiously optimistic about future growth.Read More>---
ELUT Stock 12 Month Forecast
Average Price Target
$10.00
▲(106.61% Upside)
Technical Analysis
Best Analysts Covering ELUT
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+42.77%
reiterated a buy rating 20 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +42.77% per trade.
---